Pressrelease

Isofol appoints Gustaf Albèrt as Chief Financial Officer

Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt will strenghten Isofol Medical’s management team in the execution of the company’s development program of the drug candidate Modufolin®. Isofol Medical AB (publ), a clinical stage oncology company, announces the appointment of Gustaf Albèrt as […]

Isofol appoints Gustaf Albèrt as Chief Financial Officer Read More »

Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in the treatment of osteosarcoma in children and young adults, seem to prevent HDMTX toxicities with a rescue capacity and safety not less to that of standard treatment. Isofol Medical AB (publ) announces that an abstract,

Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities Read More »

Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal study ISO-CC-007, with Modufolin in metastatic colorectal cancer (mCRC). Isofol Medical AB (publ) has conducted a successful Type C meeting with United States Food and Drug Administration (FDA) as a part of of the IND

Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer Read More »

From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study are encouraging and support execution of the planned pivotal efficacy study, ISO-CC-007. To date, 38 patients with mCRC have been treated in the ongoing ISO-CC-005 study. These have received several treatment lines ranging from first

From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer Read More »

Isofols appoints Sven Erickson as Chief Commercial Officer

In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of  Sven Erickson as Chief Commercial Officer. Mr. Erickson is an experienced life Science executive and brings to Isofol a track record of success in commercialization of pharmaceuticals, international license deals and marketing, spanning more than two decades. Isofol Medical

Isofols appoints Sven Erickson as Chief Commercial Officer Read More »

Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera, a seasoned industry executive, has joined Isofol as advisors to its Board of Directors. Isofol Medical AB (publ), a clinical stage oncology company, announces that a cooperation has been established with Professor Sten Nilsson and Doctor

Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin® Read More »

Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking place 8-12th of September in Madrid. The accepted abstract describes the first clinical study results of Modufolin® as rescue therapy to be administrated after High Dose Methotrexate (HDMTX) treatment in osteosarcoma patients. Isofol Medical AB

Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017 Read More »

Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol Medical AB, regarding the fundamental strategy behind the company’s recent IPO and important lessons learned from that process. The article has been made available and can be read via the link below: https://dev.isofolmedical.com/wp-content/uploads/2017/07/ExecutiveInterviewScrip.pdf Scrip intelligence

Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical Read More »

Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The study, which is part of the regulatory documentation required for an oncology drug to be granted approval, investigates possible effects of Modufolin on heart rhythm (ECG). The ISO-FF-001 is performed under an IND at the

Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001 Read More »

New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which further support the scientific rationale underlying the development of Modufolin® as to improve the treatment results for patients with colorectal cancer. Isofol Medical AB (publ), a clinical staged oncology company, announced today that at the

New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study Read More »

Scroll to Top